Department of Vitreo-retina and Uveitis, Shri Sadguru Seva Sangh Trust, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh; Department of Ophthalmology, Hind Institute of Medical Sciences, Sitapur, Uttar Pradesh, India.
Department of Vitreo-retina and Uveitis, Shri Sadguru Seva Sangh Trust, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh, India.
Indian J Ophthalmol. 2022 Apr;70(4):1302-1306. doi: 10.4103/ijo.IJO_1788_21.
To study the safety and efficacy of pre-operative suprachoroidal triamcinolone acetonide (SCTA) for achieving reduction/resolution of serous choroidal detachment (CD) associated with rhegmatogenous retinal detachment (RRD).
This was a prospective, noncomparative, interventional pilot study. All consecutive patients presenting with RD and coexisting CD underwent transconjunctival injection of SCTA before proceeding with vitrectomy/scleral buckle surgery. Sequential ultrasound B scans were performed for assessing the change in height of the CD.
The mean age of the cohort was 53.8 ± 10.8 years (range: 39-72 years). The CD was present in a median of 3 quadrants; the cumulative mean CD height was 5.59 mm (range: 2.02-9.42 mm). Following SCTA, a successful response (>50% reduction) was seen in five eyes by day 3 and in two eyes by day 5. Three eyes failed to respond to SCTA and required surgical drainage before proceeding with vitrectomy. No intraprocedural injection-related complications were noted. A transient rise in the intraocular pressure (30 mmHg) was seen in one eye following vitrectomy and was managed successfully with topical antiglaucoma medications.
Suprachoroidal administration of triamcinolone appears to be a safe and effective technique to achieve CD resolution in eyes with RRD.
研究术前玻璃体内曲安奈德（SCTA）在实现与孔源性视网膜脱离（RRD）相关的浆液性脉络膜脱离（CD）消退/缓解中的安全性和有效性。
这是一项前瞻性、非对照、干预性初步研究。所有伴有 CD 的 RD 患者均在接受玻璃体切除术/巩膜扣带术前行玻璃体内 SCTA 注射。连续进行超声 B 扫描以评估 CD 高度的变化。
队列的平均年龄为 53.8 ± 10.8 岁（范围：39-72 岁）。CD 存在于中位数 3 个象限中；累积平均 CD 高度为 5.59 毫米（范围：2.02-9.42 毫米）。在 SCTA 后，3 天内 5 只眼有成功反应（>50%的减少），5 天内 2 只眼有成功反应。3 只眼对 SCTA 无反应，在进行玻璃体切除术前需要手术引流。未观察到术中注射相关并发症。1 只眼在玻璃体切除术后出现短暂的眼压升高（30mmHg），经局部抗青光眼药物治疗成功控制。
玻璃体内给予曲安奈德似乎是一种安全有效的技术，可实现 RRD 眼中 CD 的消退。
